{"nct_id":"NCT06350097","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","status_verified_date":"2025-07","start_date":"2024-04-29","start_date_type":"ACTUAL","primary_completion_date":"2028-03-21","primary_completion_date_type":"ESTIMATED","completion_date":"2032-05-25","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}